当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3159
Marko Velimirovic 1 , Teodora Kuzmanovic 1 , Maedeh Zokaei Nikoo 2 , Lesil Brihn 1 , Vicky Konig 1 , Tejuana Watson 1 , Teana Austin 1 , Lauren Bokovitz 1 , Tapas Ranjan Behera 1 , Gabriel Savage 3 , Megan Kilbane 4 , Elizabeth M. Azzato 1 , Zheng Jin Tu 1 , Wen Wee Ma 1 , Roberto Vargas 1 , Jacob Miller 1 , Emrullah Yilmaz 1 , Ying Ni 5
Affiliation  

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3159-3159, June 2024.


中文翻译:


在现实环境中使用聚(ADP-核糖)聚合酶抑制剂(PARPi)治疗的晚期卵巢癌、乳腺癌和前列腺癌患者的临床病理学和基因组特征。



《临床肿瘤学杂志》,第 42 卷,第 16 期_suppl,第 3159-3159 页,2024 年 6 月。
更新日期:2024-05-30
down
wechat
bug